In the Aquaculture industry, which is in charge of sustainably supplying food of marine and freshwater origin (fish, mollusks, crustaceans, among others), there are risks that compromise production and sometimes put producers in very critical circumstances. Sanitary issues, caused by accumulated outbreaks which affected the shrimp farming industry in the past two decades, provoked the collapse of this activity in several countries. Therefore, the implementation of recombinant vaccines, probiotics and immunostimulating substances, instead of antimicrobial agents (antibiotics), has been a proposal recommended by the scientific community for the aquaculture industry. Given the volume of production, the implementation of a health prevention measure demands a cost-benefit analysis whose objective should be focused on minimizing costs and maximizing benefits in order to expand its use on a commercial scale. In Mexico, the costbenefit assessment of the implementation of recombinant immunostimulants, in species of great comercial demand (such as shrimp), has not yet been finalized, which opens a window of opportunity for their attention. This study aims to elucidate the economic potential for the production of oral vaccines manufactured in plants in order to control the Acute Hepatopancreatic Necrotic Disease (AHPND) in the farmed whiteleg shrimp (L. vannamei); additionally, aims to evaluate the cost-benefit ratio obtained through the implementation of such vaccine in a Penaeid farming system, consequently after optimizing the production parameters at small scale, generating and visualizing graphically the biggest net present value and maximum economic yield within the system.